CLINICAL TRIALS PROFILE FOR ATIPRIMOD
✉ Email this page to a colleague
Clinical Trials for Atiprimod
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00086216 ↗ | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | Completed | Callisto Pharmaceuticals | Phase 1/Phase 2 | This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma. |
NCT00214838 ↗ | An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer | Unknown status | Callisto Pharmaceuticals | Phase 1/Phase 2 | The primary objectives of this study are to identify the maximum tolerated dose and to evaluate safety of atiprimod in patients with advanced cancer. |
NCT00388063 ↗ | Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | Completed | Callisto Pharmaceuticals | Phase 2 | This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide) or progression of neuroendocrine tumor(s). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Atiprimod
Condition Name
Clinical Trial Locations for Atiprimod
Trials by Country
Clinical Trial Progress for Atiprimod
Clinical Trial Phase
Clinical Trial Sponsors for Atiprimod
Sponsor Name